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1 Introduction 
1.1 Articular cartilage 
Articular cartilage is an avascular, alymphatic and aneural tissue that covers the ends of 
synovial joints and thereby represents a unique tissue of the human body. Due to its 
characteristics and matrix composition, this tissue is called hyaline cartilage, which is also 
present in the respiratory tract and the cartilaginous parts of the ribs [1]. Further types of 
cartilage are fibrocartilage and elastic cartilage. Fibrocartilage is characterized by a majority of 
unmasked collagen type I fibres with single cells or in a linear arrangement between these 
fibres. It is present in tissues such as the menisci or in the outer fibrous ring of intervertebral 
discs. Elastic cartilage can be found in parts of the auricle and the larynx and is similar to 
hyaline cartilage, but contains additional elastic fibres [2].  
The main function of articular cartilage is to compensate for mechanical impacts and minimize 
the friction of opposing cartilage surfaces during movements. This functionality is provided by 
a complex composition of extracellular matrix (ECM) molecules consisting of collagens, 
proteoglycans and non-collagenous proteins. The ECM 
content in healthy cartilage is >95% of its dry weight [3].  
Articular cartilage shows a unique architecture with different 
zonal structures distinguishable from each other by ECM 
composition, ECM orientation, cell shape and cell 
arrangement (Figure 1). The superficial zone contains 
flattened cells and horizontally orientated collagen fibres. In 
combination with lubricin from the synovial fluid, the friction 
of the cartilage surface is minimized [4].  
The subjacent transitional zone is characterized by 
increased proteoglycan content and a round-shaped cell 
morphology. The deep zone shows the lowest cell density 
with the highest concentration of proteoglycans and 
vertically-arranged collagen fibres. The demarcation 
between the deep zone and calcified cartilage is called the 
tidemark. It provides a tethering structure for the collagen 
fibres above, thereby preventing cartilage detachment from 
the subchondral bone. The calcified cartilage defines the 
transition from cartilage to the subchondral bone below, in 
which bone marrow is situated [3].  
 
Figure 1: Cryosection of healthy 
adult ovine hyaline cartilage 
stained by Safranin O and Fast 
green. Cell nuclei appear black. 
The white dotted line indicates the 
tidemark; scale bar 200 µm. 
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There is only one cell type in articular cartilage, namely the chondrocytes. These cells are 
highly specialized to sustain the surrounding ECM. In humans, healthy articular cartilage 
contains about 9.6x103 chondrocytes/mm3 [5]. Chondrocytes are rarely capable of forming 
direct cell-cell contacts as they are completely surrounded by the ECM. The functional complex 
of a chondrocyte and the direct surrounding matrix is called the “chondron” and is responsible 
for the final ECM synthesis [6]. 
Since 1743, when William Hunter described defects in articular cartilage as “a very 
troublesome disease;… and that, when destroyed, it is never recovered” [7], the dogma of the 
absence of an insufficient, intrinsic repair mechanism in articular cartilage persists.  
 
1.2 Cartilage lesions 
Articular cartilage lesions remain one of the major problems in orthopaedic medicine. The most 
common cartilage disorders are osteoarthritis (OA) and rheumatoid arthritis [8]. The following 
chapter will focus on degenerative and traumatic cartilage lesions, prospectively treatable by 
regenerative tissue engineering approaches.  
OA is the most common joint disease in the industrialised world with about “10% men and 13% 
… women aged 60 years or older” affected people in the United States [9] and 13.9% men and 
21.8% women affected people in Germany in 2017 [10]. The prevalence of OA is increasing 
due to an aging population and obesity. It develops gradually over several years, whereby the 
symptoms, characterized by cartilage damage, changes of the subchondral bone and 
inflammation of the synovial tissue can progress in spurts [11]. Joint malalignment, mechanical 
stress and catabolic tissue enzymes induce the release of breakdown products of the ECM 
from cartilage, which further causes inflammation of the synovial membrane. This process 
initiates the production of proinflammatory cytokines, collagenases and other hydrolytic 
enzymes from synovial cells and local macrophages [12]. A vicious positive feedback loop 
involving cartilage breakdown and synovial inflammation occurs [13]. Since OA is 
characterized by a slow disease progression, the initial starting point of the disease is difficult 
to define, as symptoms arise late. A traumatic injury of the joint might be one of the main 
initiators of cartilage breakdown. Hence a therapeutic intervention for primary traumatic 
cartilage defects is seen as a promising approach to prevent progression to secondary OA 
(Figure 2) [14]. 
The risk of developing OA is >40% after ligament and meniscus tears as well as after cartilage 
surface injuries [15]. The more severe the initial damage, the earlier the progression of OA will 
start. The pathology of development of secondary OA after a traumatic cartilage defect is 
characterized by an initial inflammatory response and the onset of ECM restoration, which 
formally leads to a fibro-cartilaginous tissue with poor mechanical properties.  
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The inflammation process is not only restricted to cartilage tissue, but also spreads to the bone, 
synovial membrane, ligaments and meniscus. Following this, proinflammatory mediators are 
detectable in the synovial fluid. The pathologic progression leads to fissures in the cartilage, 
which are accompanied by cartilage destruction until it reaches the subchondral bone. The 
disease procession is than comparable with the pathologic stages of OA [16]. 
Depending on the defect depth and the involvement of the subchondral bone, an intrinsic 
cartilage regeneration process arises, providing a promising target cell population for 
regenerative medicine.  
 
1.3 Self-healing capability of articular cartilage 
The self-healing capability of cartilage defects can be driven by mesenchymal progenitor cells 
from within the articular cartilage [17] or mesenchymal stromal cells (MSC) which are infiltrating 
the defect site from the subchondral bone [18].  
From human embryonic limb buds, it is known that chondrogenesis harbours two different 
subpopulations of multipotent cartilage stem cells and oligopotent cartilage progenitor cells 
[19]. In 2004, two research groups published in parallel findings on adult “mesenchymal 
progenitor cells” in osteoarthritic cartilage. These progenitor cells can be characterized by the 
expression of CD166 (cluster of differentiation 166) and the co-expression of CD105 [20] or 
either CD90 [21] and their in vitro adipogenic, osteogenic and chondrogenic (trilineage) 
differentiation potential. Chondrocytes derived from OA-affected tissue also showed increased 
chondrogenic potential, predominantly by higher expression of sulphated glycosaminoglycans 
[22]. In 2011 mesenchymal progenitor cells with a comparable phenotype were also identified 
in biopsies of macroscopically healthy cartilage [23]. 
Another self-healing mechanism of cartilage defects arises from MSCs from the subchondral 
bone marrow, as cartilaginous deposition has been detected within the subchondral bone in 
patients with severe OA. It is hypothesised that these aggregates arise from MSCs and might 
 
Figure 2: Arthroscopic photographs of the human knee (left) of healthy cartilage, (middle) a focal 
cartilage lesion and (right) secondary osteoarthritis. The femur and tibia are indicated by capital letters 
“F” and “T”.  
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support resurfacing of destroyed articular cartilage [24,25] by migrating through the tidemark 
[18,26]. The synovial fluid is known to support such a migration [27]. However, the progression 
of degenerative cartilage diseases shows, that these intrinsic repair mechanisms alone cannot 
lead to a full recovery. Hence, surgical treatment options or novel regenerative procedures are 
required to sustain or improve the patients’ welfare.  
 
1.4 Treatment option for cartilage lesions 
The treatment of a cartilage defect in order to restore joint function and improve patient 
wellbeing is the ideal goal. A variety of possible treatment options are currently available 
depending on the defect size, the patient´s activity level and the patient´s age [28]. An overview 
is given in Figure 3. 
The most frequent conventional treatment option for small focal cartilage defects is the 
microfracture or Pridie drilling, as it is a single-stage procedure with a minimal morbidity of 
healthy surrounding cartilage [29]. In the intervention, the defect site is cleared of loose 
cartilage fragments and the subchondral bone is drilled multiple times to provoke a bleeding 
of bone marrow and a formation of a bone marrow clot. This clot contains MSCs which induce 
spontaneous formation of scar-like tissue. Microfracture is recommended as first-line treatment 
for isolated defects of <2.5 cm². particularly in younger patients [29–31]. Despite a short-term 
improvement in functionality, the fibrous cartilage lacks of mechanical durability and long-term 
stability [32].  
An improvement in long-term stability can be achieved with the Osteoarticular Transfer System 
(OATS). With this technique, osteochondral plugs from a non- or lesser-weight-bearing region 
 
Figure 3: Treatment schedule for cartilage defects according to defects size, patients level of activity and 
age adopted from [28]. # International Cartilage Repair Society classification [33,34].  
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of the joint are transferred to the former defect site. The advantage is an immediate restoration 
of the mechanical function of the tissue [35]. The donor-site morbidity limits the size of treatable 
defects and the integration of implanted cartilage pieces is poor. To overcome the donor-site 
morbidity, allograft osteochondral plugs are frequently used. With this, the application of fresh 
donor material is highly recommended as stored plugs show poor chondrocyte viability and 
worse biomechanical properties [35,36]. A further limitation of allografts is the risk of disease 
transmission and immunological reactions [37].  
Cell-free approaches are a faster, cheaper, off-the-shelf and easy-to-use alternative. The basic 
principle addresses the support of the defect side by stabilizing the defect borders, providing 
a mechanically stable structure to cope with load-bearing and shear forces, limiting the ongoing 
degenerative process and supporting the intrinsic regeneration. A broad range of medical 
products are commercially available. Further product developments are focusing on “smart 
materials” and “stimulant-combined” products. Smart materials can include zonal layered 
structures to mimic the natural structure of the ECM of hyaline cartilage (e.g. 3D-printed 
scaffolds), while stimulant-combined scaffolds are a combination of a matrix structure with 
incorporated growth factors or pharmaceuticals [38]. The included substances can either 
stimulate the proliferation and differentiation of adjacent cells or treat local inflammations and 
degenerative processes. However, the clinical benefit of cell-free approaches must be 
examined in high-quality studies [39]. 
In 1994 Brittberg et al. described a regenerative approach in cartilage defect treatment, the 
autologous chondrocyte transplantation (ACT). In this technique, chondrocytes from a biopsy 
of an unaffected area of the joint were isolated and expanded in vitro for 14-21 days. The 
expanded chondrocytes were injected in the defect area and covered with a periosteal flap 
from the tibia [40]. This first-generation ACT was associated with limitations such as leakage 
of cell suspension after periosteal flap detachment, periosteal hypertrophy and chondrocyte 
dedifferentiation after extensive monolayer expansion [36]. To overcome some of the 
disadvantages of this technique, the cell suspension was combined with scaffolds to provide 
a homogenous distribution and retention of cells within the transplant. This technique is known 
as second-generation ACT, or matrix-assisted ACT (MACT) [41]. The clinical application of 
MACT techniques show superior results when compared to other interventions such as 
microfracture [42]. However, MACT is limited by donor site morbidity, the available cell pool of 
chondrocytes, their dedifferentiation during extensive in vitro expansion and their reduced 
ability to re-differentiate [43,44]. Major complications after implantation such as cartilage 
hypertrophy, insufficient bonding to the surrounding healthy cartilage, and formation of 
insufficient regenerative cartilage tissue or delamination from the subchondral bone are still 
seen in clinical practice [45], despite optimization of application techniques [46] and the 
selection of potent chondrocytes [14]. Major improvements can be expected from the 
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substitution of the chondrocytes as stated by the editors in chief of the journal Arthroscopy: 
“The ultimate goal is a single-step, tissue-engineered solution to focal cartilage defects, and 
elimination of the morbidity of the donor defect.” [47].  
Therefore, MSCs seem to be a promising candidate to fulfil the requirements of an optimal 
cartilage defect treatment procedure [48]. 
 
1.5 Mesenchymal stromal cells in cartilage regeneration 
Friedenstein et al. were the first to describe fibroblast colony-forming units (CFU-Fs) from bone 
marrow [49]. Caplan et al. named these cells MSCs in the early 1990s [50]. These cells have 
a native non-haematopoietic, nonendothelial character with topographically diverse niches in 
bone marrow [51] and several other tissues including synovial membrane, muscle, fat, dental 
pulp and others [37]. They are located in perivascular or bone-lining niches [52] and their native 
phenotype can be described based on the expression of CD271 [53] and CD140b [54], while 
they are negative for CD34, CD14, CD45, CD11b, CD49d, CD106, CD10 and CD31. The 
frequency of native MSCs in bone marrow aspirate ranges from 0.0017% to 0.0201% of the 
mononuclear cells [55], but only about 10% of these show a true colony formation under in 
vitro monolayer conditions [56], which makes them extraordinarily rare cells in bone marrow. 
However, their high expansion potential, anti-inflammatory and immunomodulatory paracrine 
effects [57] as well as multipotent differentiation potential, including the potential to differentiate 
into chondrocytes [58], make them an ideal candidate for regenerative medicine [59].  
The characterization of isolated, in vitro expanded MSCs was defined by the current guideline 
of the International Society for Cellular Therapy (ISCT) based on three compliance criteria: 
“First, MSC must be plastic-adherent when maintained in standard culture conditions using 
tissue culture flasks. Second, >95% of the MSC population must express CD105, CD73 and 
CD90, as measured by flow cytometry. Additionally, these cells must lack expression (≤2% 
positive) of CD45, CD34, CD14 or CD11b, CD79a or CD19 and HLA class II. Third, the cells 
must be able to differentiate to osteoblasts, adipocytes and chondroblasts under standard in 
vitro differentiating conditions.” [60]. 
Numerous preclinical studies have been performed using MSCs with promising results on 
cartilage regeneration [61–63]. Minor side effects of the first attempts were reported as 
calcification of implanted tissue, fibrogenesis, and heterotopic tissue formation in the cartilage 
[45]. These drawbacks could be reduced by a preconditioning of expanded MSCs to 
chondrogenic differentiation such as with supplementation with transforming growth factor β3 
[63–65]. 
Several case studies, randomized and comparative clinical studies showed the general ability 
of autologous, bone marrow-derived, expanded MSC transplantation to repair articular 
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cartilage defects [48]. Early applications of MSCs in human cartilage repair have reported 
follow-up of up to 11 years without infection or tumour formation, proving the safety of the 
therapeutic application of MSCs [66]. However, the potential for malignant changes during 
clinical use of MSC is still an important aspect [67,68]. Therefore, stringent safety, purity and 
potency measures are required to ensure patient safety [69,70]. In particular, in vitro cell 
expansion strategies present a risk of contamination, transformation or chromosomal 
aberrations [71]. Appropriate risk minimization could be achieved by elimination or reduction 
of cultivation time, limitation of the number of population doublings, monitoring of cytogenic 
aberrations and testing sterility, phenotype and viability [59,72].  
Multiple approaches highlight the application of allogenic, in vitro expanded MSCs as an “off-
the-shelf” product. A major drawback for allogenic MSC approaches is an increased 
immunogenic potential of MSCs after chondrogenic differentiation. This might be due to 
increased expression of MHC-I and MHC-II receptors [73]. Furthermore, chondrogenically 
differentiated MSCs lose their ability to suppress dendritic cell function [74] as well as to 
suppress activated CD4+ and CD8+ T cells [73], which makes them detectable by the host 
immune system [57]. Therefore, autologous cell sources should be preferred to allogenic 
approaches.  
The major drawbacks of an in vitro expansion based two-stage procedure could be bypassed 
by single-stage preparation of cartilage graft with highly potent, non-expanded MSCs. One of 
the most promising marker candidates for prospective separation of these potent, non-
expanded MSCs is CD271 [56,75–83]. CD271, also known as low-affinity nerve growth factor 
receptor, was first described by Chesa and Thomson et al. in 1988. It is involved in survival 
and developmental signalling in neuronal cells. Histological analysis revealed additional 
expressions in epithelial, mesenchymal and lymphoid tissues [84]. The function of CD271 on 
MSCs is currently unknown, although it affects the morphogenesis, growth factor stimulation 
and the prevention of cells from apoptosis [81]. However, CD271+ MSCs contain the majority 
of CFU-Fs [81] with an increased chondrogenic potential compared to non-separated MSCs 
[79,85,86]. The marker is downregulated during monolayer expansion; therefore, it is only a 
potent marker for native MSC isolation [87]. CD271+ cells were already found to be involved in 
spontaneous cartilage repair in joint explant cultures [88]. Jones et al. proved the ability of a 
clinical feasible separation strategy based on magnetic cell separation (MACS) for non-union 
bone fractures [89]. This procedure could be transferable to cartilage defects. However, to the 
author´s best knowledge, no single-stage procedure for CD271+ separated cells from bone 
marrow for cartilage defect therapy has been reported previously in the literature.  
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2 Rationale 
Regenerative treatment of hyaline cartilage focal defects could prevent the development of 
secondary OA. The common use of bone marrow stimulating techniques results partly in 
formation of mechanically inferior fibrous cartilage, which increases the need for improved 
interventions with a long-term perspective. Chondrocyte-based procedures like MACT present 
the disadvantages of donor site morbidity, dedifferentiation of chondrocytes due to ex vivo 
expansion and reduced re-differentiation potential. 
The self-healing capacities of injured and degenerated cartilage revealed a promising target 
cell population for a regenerative, autologous single-stage procedure for the treatment of these 
defects using non-expanded MSCs from the bone marrow. Currently available clinical 
approved cell separation devices enable for intraoperative purification of CD271+ cells, which 
contain the majority of colony-forming MSCs, by MACS technology. By providing a hydrogel 
with non-expanded CD271+ cells, the advantages of a MACT approach could be combined 
with the need for a “single-step, tissue-engineered solution to focal cartilage defects, and 
elimination of the morbidity of the donor defect” [47]. 
The preliminary experiment regarding CD271+ cells from bone marrow of adult sheep was 
published in the Journal of Tissue Engineering and Regenerative Medicine in May 2018 [90]. 
Therein, four single marker candidates were tested for their effectiveness of separating 
ovine MSCs via MACS and the feasibility to generate cartilage grafts from non-expanded 
CD271+, CD271- and unseparated ovine MNCs. 
The present in vitro study investigated the feasibility of generating cartilage grafts from human 
CD271+ bone marrow cells in a CE-marked collagen type I hydrogel without initial monolayer 
expansion. Cell viability, DNA content, chondrogenic differentiation capacity, extracellular 
matrix secretion, and graft properties were monitored for up to 5 weeks to investigate the 
single-stage therapeutic approach for human focal cartilage defects. 
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4 Summary 
Regenerative treatment of focal hyaline cartilage defects could prevent or delay the 
development of secondary osteoarthritis. Current surgical techniques result partly in i) the 
formation of mechanically inferior fibrous cartilage or ii) present the disadvantage of the donor 
site morbidity from harvesting cartilage biopsy as well as iii) the dedifferentiation of 
chondrocytes due to in vitro expansion and iv) the reduced re-differentiation potential of in vitro 
expanded chondrocytes.  
 
The self-healing capacities of injured and degenerated articular cartilage revealed a promising 
target cell population for a regenerative, autologous treatment of these defects using 
mesenchymal stromal cells (MSCs). Several case studies, randomized and controlled clinical 
studies showed the general ability of autologous, bone marrow-derived, expanded MSC 
transplantation to regenerate articular cartilage lesions [48]. However, these two-stage 
approaches are based on time- and cost-consuming expansion of MSCs under good 
manufacturing practice (GMP) conditions and hold a risk of contamination during this process.  
 
In 2010, CD271, the low-affinity nerve growth factor receptor, was described as a suitable 
surface marker to enrich MSCs from human bone marrow aspirate intraoperatively [56]. 
The aim of the present dissertation was to investigate the feasibility of generating cartilage 
grafts from either ovine (study no. 1) and human (study no. 2) non-expanded CD271+ bone 
marrow cells in a collagen type I hydrogel. 
 
Study no. 1 (“Point-of-care treatment of focal cartilage defects with selected chondrogenic 
mesenchymal stromal cells - An in vitro proof-of-concept study”) investigated several surface 
marker candidates for the prospective MSC separation and examined their potential of 
resulting colony-forming units, respective their yield of potent MSCs [90]. This study was 
conducted with ovine bone marrow samples. CD271 was the most effective surface marker to 
isolate the target cell population. Subsequently, CD271+, CD271- and unseparated 
mononuclear cells (MNCs), containing the MSCs, were used to generate cartilage grafts 
without an expansion of these cells in monolayer culture. It could be proven, that ovine CD271+ 
cells were able to generate a potent hyaline cartilage graft. 
 
Study no. 2 (“Single-stage preparation of human cartilage grafts generated from bone marrow-
derived CD271+ mononuclear cells”) was performed as the final translational step from animal-
derived bone marrow to human donor material and is therefore strengthening the 
therapeutically focus of the entire work [91]. 
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Briefly, eight bone marrow aspirates were used for MNC isolation and subsequent magnetic 
cell separation (MACS). The resulting CD271+ and CD271- MNCs were compared to 
unseparated MNCs. Subsequently, they were seeded in a clinically approved collagen type I 
hydrogel and cultivated for up to 5 weeks to investigate the progression of the chondrogenic 
differentiation processes. Graft analysis included cell viability visualization by live/dead 
staining, determination of the DNA and the secreted sulphated glycosaminoglycan (sGAG) 
content as well as the immunohistochemical staining for typical chondrogenic differentiation 
markers and the extracellular matrix molecules aggrecan and collagen type II.  
 
A proliferation of cells in the generated grafts was shown of CD271+ and unsep, but not CD271- 
MNCs. Hence, the cell number was 2.8-fold higher after 35 days compared to the first day for 
CD271+ MNCs grafts, while CD271- MNCs did not proliferate in the grafts and unsep MNCs 
showed only a slight increase in cell number.  
The chondrogenic potential was measured by quantification of freshly produced sGAGs and 
the expression of chondrogenic markers. In grafts with CD271+ MNCs, sGAG production 
increased over time and reached its maximum at day 35, whereas grafts with CD271- MNCs 
showed no measurable sGAG deposition. The amount of sGAG in unsep MNC grafts 
increased only slightly over the whole cultivation period. Aggrecan and collagen type II staining 
varied considerably between the MNCs donors. Collagen type II positive staining was 
observed in CD271+ MNC grafts (5/8 donors) and unsep MNC (2/8) grafts. In comparison to 
macroscopically healthy cartilage, three-dimensional grafts of the CD271+ group yielded a 
proceeding extracellular matrix production. 
In summary, CD271+ MNCs showed the highest proliferation rate, cell viability, sGAG 
deposition and cartilage marker expression compared to the CD271- or unseparated MNC 
fractions in in vitro generated three-dimensional cartilage grafts.  
Therefore, the presented work demonstrated the feasibility of generating a cartilage graft from 
CD271+ bone marrow-derived MNCs in a clinically approved collagen type I hydrogel without 
a previous monolayer expansion of these cells. This will enable the intraoperative purification 
of CD271+ MNCs, which contain the majority of colony-forming MSCs, by MACS technology. 
The clinical application will be possible with currently available and clinical approved cell 
separation devices.  
 
Providing a cartilage graft with non-expanded CD271+ MNCs by a fast and simple 
intraoperative therapeutic approach fulfils the need for a “single-step, tissue-engineered 
solution to focal cartilage defects, and elimination of the morbidity of the donor defect” as 
requested by the editors of the journal Arthroscopy [47]. 
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6 Appendix 
Appendix to manuscript “Point-of-care treatment of focal cartilage defects with selected 
chondrogenic mesenchymal stromal cells - An in vitro proof-of-concept study”: 
 
 
Figure S1: Positive and negative controls for immunohistochemical staining. Human 
adult hyaline cartilage was used as a control for each antigen staining. Images are 
displayed in 100× magnification. 
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Appendix to manuscript “Single-stage preparation of human cartilage grafts generated 
from bone marrow-derived CD271+ mononuclear cells”: 
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